Sorry, you need to enable JavaScript to visit this website.

All materials and content available on the website are of strictly non-promotional nature and only intended for healthcare professionals (HCPs) practicing in Europe. Kindly note that materials and content are not intended for any specific country and approval conditions for products may vary from country to country. Before prescribing any product, always refer to the approved label in the relevant country and/or the Summary of Product Characteristics.

  • December 12, 2022
  • CKD-MBD and SHPT

Early intervention for secondary hyperparathyroidism in patients with non-dialysis CKD

Explore the science
  • October 11, 2022
  • Glomerular Disease

Guiding you through Glomerular Disease: an interactive approach to learning more on IgAN and FSGS

Explore the science
  • October 11, 2022
  • Glomerular Disease

IgAN Mechanism of Disease

Explore the science
  • October 11, 2022
  • Glomerular Disease

FSGS Mechanism of Disease

Explore the science
  • September 05, 2022
  • CKD-MBD and SHPT

A shift in focus: International insights into the optimal management of CKD-MBD

Explore the science
  • September 05, 2022
  • Hyperkalemia

Global Heart Failure Academy

Explore the science
  • July 07, 2022
  • ANCA-associated vasculitis

The science of complement antagonism in ANCA vasculitis – current understanding

Explore the science
  • June 30, 2022
  • ANCA-associated vasculitis

Avacopan as first-line treatment in antineutrophil cytoplasmic antibody-associated vasculitis: A steroid-sparing option

Explore the science
  • June 30, 2022
  • ANCA-associated vasculitis

Compassionate use of Avacopan in difficult-to-treat ANCA-associated vasculitis

Explore the science